跳至主要内容
临床试验/JPRN-UMIN000022831
JPRN-UMIN000022831已完成未知

Anti-TNF-Study Utilizing Biomarker Assay to Monitor Early Response to Certolizumab Pegol - TSUBAME Study

niversity of Occupational and Environmental Health, Japan0 个研究点目标入组 100 人开始时间: 2016年8月2日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patients were excluded if they had history of demyelinating or convulsive disease of the central nervous system (e.g., multiple sclerosis and epilepsy), New York Heart Association Class III or IV congestive heart failure, infectious disease, hepatitis B or hepatitis C, malignant tumor or lymphoproliferative disorder, including lymphoma or signs and symptoms suggestive of lymphoproliferative disease. Patients with any indication of current or past tuberculosis as shown by clinical history, chest X-ray and/or positive tuberculin reaction test were also excluded unless preventive therapy by isoniazid was first taken.

研究者

发起方
niversity of Occupational and Environmental Health, Japan

相似试验